Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma (Nasdaq: CBIO) will present at two investor conferences in March 2026: TD Cowen on March 2 at 3:50 p.m. ET in Boston and Leerink Partners on March 11 at 8:40 a.m. ET in Miami.
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) will present at two investor conferences in March 2026: TD Cowen on March 2 at 3:50 p.m. ET in Boston and Leerink Partners on March 11 at 8:40 a.m. ET in Miami.
According to Crescent Biopharma, each presentation will be webcast live and replays will be available via the Investors section of the company's website for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CBIO
On Feb 23, the day this news came out, CBIO closed 1.55% below the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- TD Cowen conference edition
- 46th
- TD Cowen 46th Annual Health Care Conference
- TD Cowen presentation time
- 3:50 p.m. ET
- Fireside chat on Monday, March 2, 2026
- TD Cowen presentation date
- March 2, 2026
- TD Cowen Health Care Conference in Boston
- Leerink presentation time
- 8:40 a.m. ET
- Fireside chat on Wednesday, March 11, 2026
- Leerink presentation date
- March 11, 2026
- Leerink Partners 2026 Global Healthcare Conference in Miami
- Webcast replay period
- 90 days
- Replay of conference webcasts on investor relations site
Historical Context
-
IND clearances for CR-001 and CR-003 oncology programs with ASCEND plan.
-
Employee inducement equity option awards under 2025 plan with 10-year term.
-
Guggenheim biotech summit fireside chat with webcast and 90-day replay.
-
First patient dosed in ASCEND Phase 1/2 CR-001 trial for solid tumors.
-
Inducement option grants totaling 24,600 shares to non-executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:
- TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.
- Leerink Partners 2026 Global Healthcare Conference, fireside chat on Wednesday, March 11, 2026 at 8:40 a.m. ET in Miami.
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.